Semaglutide News and Research

Latest Semaglutide News and Research

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics (OADs) combined with a GLP-1 receptor agonist do not provide adequate glycaemic control. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this fixed combination offers an added benefit over the appropriate comparator therapy (ACT).

19 Nov 2015

Diabetes drug liraglutide ineffective in patients with advanced heart failure

In an attempt to correct defects in the energy generation that contributes to poor pump function among heart failure patients, researchers examined whether the diabetes drug liraglutide, could improve the condition of patients with advanced heart failure. Despite improvements in blood sugar control, the therapy did not improve the clinical stability or pumping action of the heart in patients with advanced heart failure.

9 Nov 2015

New generation of incretin-based medicines allows coordinated action against diabesity

The new generation of incretin-based medicines will allow a coordinated action against the combination diabetes/obesity, also known as diabesity, in some cases with only a single weekly dose, and with the likelihood of additional beneficial effects on other health complications related to this condition, such as cardiovascular and neurodegenerative diseases.

28 Oct 2015

Type-2 diabetes medication can affect the brain's reward system, reduce intake of food

Many studies have focused on how much we eat when we are hungry, but sometimes we eat just to feel better. A new dissertation at Sahlgrenska Academy shows that medication used for type-2 diabetes wich mimics the gut-brain hormone glucagon-like peptide-1, can affect the brain's reward system and reduce the intake of food.

29 Sep 2015

Medication used for diabetes could be a valuable tool for treating alcohol dependence

A new study on mice and rats at Sahlgrenska Academy shows that a medication used for diabetes and obesity also could be a valuable tool for the treatment of alcohol dependence.

25 Sep 2015

New study highlights gap in scientific knowledge about some diabetes drugs

A gap in scientific knowledge about a family of drugs that are used to treat Type 2 diabetes has been highlighted in a new study.

21 Sep 2015

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).

16 Sep 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.

18 Aug 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.

12 Aug 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.

29 Jul 2015

GLP-2 therapy may help fight neonatal parenteral nutrition-associated liver disease

A new study finds that exogenous glucagon-like peptide 2 (GLP-2) treatment may help fight neonatal parenteral nutrition-associated liver disease (PNALD).

28 Jul 2015

Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration.

30 Jun 2015

CTI Biotechnology implements Xybion's Pristima 7 Preclinical Suite

Xybion Corporation, leading provider of preclinical R&D solutions announced today that CTI Biotechnology in Suzhou, China has implemented Xybion's Pristima 7 Preclinical Suite. Pristima® was selected after an exhaustive evaluation of top selling preclinical software systems on the market.

30 Jun 2015

ASEAN poised to be the next economic powerhouse of Asia

With a 600 million plus population and pharmaceutical market demand of USD21.3 billion in 2014, Association of Southeast Asian Nations (ASEAN) is poised to be the next economic powerhouse of Asia, through efforts such as the ASEAN Harmonization and Bioeconomy Transformation Programme.

27 Jun 2015

Sysmex unveils latest series of haematology analysers at IFCC congress

The Sysmex Corporation, the global leader in haematology, unveiled its latest series of haematology analysers at the annual IFCC congress, EuroMedLab JIB in Paris today. The XN-L series follows in the footsteps of its game-changing big brother, the XN-Series. The new, smaller XN-L Series makes top quality haematology available for all.

From Sysmex America, Inc. 22 Jun 2015

Treating obesity with GLP-1 hormone helps prevent loss of bone mass associated with weight loss

Using the intestinal hormone GLP-1 in obesity treatment prevents the loss of bone mass otherwise frequently associated with major weight loss. This is the finding of a new study from the University of Copenhagen, Hvidovre and Glostrup Hospital. According to the researchers behind the study, the results may have a significant bearing on future obesity treatment.

11 Jun 2015

Study shows how GLP-1 receptor agonists modify the brain's response to food

Gut hormone-based medications used to treat diabetes, such as GLP-1 receptor agonists, have also been shown to reduce body weight. Researchers have been working to understand how. This study, presented today at the American Diabetes Association's 75th Scientific Sessions, sheds light on how GLP-1 receptor agonists alter the brain's response to food, possibly reducing cravings and increasing satisfaction while eating.

9 Jun 2015

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk.

8 Jun 2015

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Intarcia Therapeutics, Inc. today announced the presentation of results from its first two phase 3 clinical trials (FREEDOM-1 and FREEDOM-1 HBL) of its late-stage investigational candidate ITCA 650 (exenatide delivered continuously via a small matchstick-size subcutaneous osmotic mini-pump just once or twice yearly) at the 75th Scientific Sessions of the American Diabetes Association.

8 Jun 2015

Semaglutide News and Research

Latest Semaglutide News and Research

IQWiG finds no added benefit for insulin degludec/liraglutide in adults with type 2 diabetes

Diabetes drug liraglutide ineffective in patients with advanced heart failure

New generation of incretin-based medicines allows coordinated action against diabesity

Type-2 diabetes medication can affect the brain's reward system, reduce intake of food

Medication used for diabetes could be a valuable tool for treating alcohol dependence

New study highlights gap in scientific knowledge about some diabetes drugs

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Ardelyx reports net income of $9.0 million for second quarter 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

GLP-2 therapy may help fight neonatal parenteral nutrition-associated liver disease

Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

CTI Biotechnology implements Xybion's Pristima 7 Preclinical Suite

ASEAN poised to be the next economic powerhouse of Asia

Sysmex unveils latest series of haematology analysers at IFCC congress

Treating obesity with GLP-1 hormone helps prevent loss of bone mass associated with weight loss

Study shows how GLP-1 receptor agonists modify the brain's response to food

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Results from Intarcia's two phase 3 clinical trials of ITCA 650 to be presented at ADA's Scientific Session

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in